Contribute Try STAT+ Today

If you’d talked to Joe Heyman around the 2000s, you might have taken him as a telemedicine naysayer. Back then, the Massachusetts OB-GYN was highly skeptical of the rash of new services sprouting up to remotely connect patients and physicians. He was wary, he told STAT, of patients “calling a total stranger and asking for clinical care,” and worried about building trust when a new doctor picked up the phone every time. He never once conducted a visit via video by the time he retired from seeing patients in 2014.

He only wishes he’d had the chance.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.